血液肿瘤学 SCIESCI

期刊简介预计审稿时间：>12周，或约稿

Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged:

-Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders

-Diagnostic investigations, including imaging and laboratory assays

-Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases

-Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies

-Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems.

Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.

血液肿瘤学考虑发表涉及造血和淋巴系统肿瘤疾病的实验和临床方面的文章以及相关事宜。特别欢迎将基础科学应用于临床问题的转化研究。鼓励涉及以下领域的手稿：

-血液肿瘤的临床实践和管理，包括：急性和慢性白血病、恶性淋巴瘤、骨髓增生性疾病

-诊断调查，包括成像和实验室检测

-血液病血液肿瘤的流行病学、病理学和病理生物学

-治疗问题，包括 1、2 或 3 期试验以及同种异体和自体干细胞移植研究

-正常或患病造血和淋巴细胞生成的细胞生物学、分子生物学、分子遗传学和细胞遗传学方面，包括干细胞和细胞因子和其他调节系统。

欢迎使用简洁的专题评论材料，特别是如果它可以让更广泛的社区接触到新概念和想法。审查材料的建议可以与主编讨论。只有当它们具有更广泛的科学或临床相关性时，才会考虑收集病例材料和病例报告。

《Hematological Oncology》(血液肿瘤学)编辑部通讯方式为JOHN WILEY & SONS LTD, THE ATRIUM, SOUTHERN GATE, CHICHESTER, ENGLAND, W SUSSEX, PO19 8SQ。如果您需要协助投稿或润稿服务，您可以咨询我们的客服老师。我们专注于期刊投稿服务十年，熟悉发表政策，可为您提供一对一投稿指导，避免您在投稿时频繁碰壁，节省您的宝贵时间，有效提升发表机率，确保SCI检索（检索不了全额退款）。我们视信誉为生命，多方面确保文章安全保密，在任何情况下都不会泄露您的个人信息或稿件内容。